JOP20200093A1 - طريقة لإنتاج مشتق ثيازول - Google Patents

طريقة لإنتاج مشتق ثيازول

Info

Publication number
JOP20200093A1
JOP20200093A1 JOP/2020/0093A JOP20200093A JOP20200093A1 JO P20200093 A1 JOP20200093 A1 JO P20200093A1 JO P20200093 A JOP20200093 A JO P20200093A JO P20200093 A1 JOP20200093 A1 JO P20200093A1
Authority
JO
Jordan
Prior art keywords
formula
production method
compound represented
thiazole derivative
disorder
Prior art date
Application number
JOP/2020/0093A
Other languages
English (en)
Inventor
Tada Atsushi
Yanagisawa Arata
Taga Masashi
Sugita Takamasa
Mimura Akihiro
Aoki Masashi
Chujo Iwao
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JOP20200093A1 publication Critical patent/JOP20200093A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

يتعلق الاختراع بطريقة لإنتاج مشتق ثيازول يتم تمثيله بواسطة الصيغة(I)، له عمل مضاد لمستقبل أدينوزين A2A ويعد مفيدًا باعتباره عاملاً علاجيًا لـ، على سبيل المثال، داء باركنسون، اضطرابات النوم، المقاومة المسكنة للمواد الأفيونية، الصداع النصفي، اضطراب الحركة، الاكتئاب، اضطراب القلق وما شابه. كما يتم أيضًا توفير طريقة إنتاج لمركب يتم تمثيلة بواسطة الصيغة(ج)، التي تحتوي على (1) خطوة إحداث تفاعل مركب يتم تمثيله بواسطة الصيغة(أ) ومركب يتم تمثيله بواسطة الصيغة(ب)، وما شابه: (حيث تمثل R1 الفوريل، تكون R4 و R5 و R6 نفسها أو مختلفة وتميل كل واحدة منها ألكيل أو أريل أدنى، تمثل R2 بيريديل أو تيترا هيدرو بيرانيل، وتمثل X1 هالوجين).
JOP/2020/0093A 2015-01-09 2015-01-09 طريقة لإنتاج مشتق ثيازول JOP20200093A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015002964 2015-01-09

Publications (1)

Publication Number Publication Date
JOP20200093A1 true JOP20200093A1 (ar) 2017-06-16

Family

ID=56356063

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0093A JOP20200093A1 (ar) 2015-01-09 2015-01-09 طريقة لإنتاج مشتق ثيازول
JOP/2016/0004A JO3546B1 (ar) 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2016/0004A JO3546B1 (ar) 2015-01-09 2016-01-07 طريقة لإنتاج مشتق ثيازول

Country Status (24)

Country Link
US (3) US10214523B2 (ar)
EP (2) EP3822269A1 (ar)
JP (2) JP6770962B2 (ar)
CN (1) CN107108602B (ar)
AR (1) AR103380A1 (ar)
AU (1) AU2016205657B2 (ar)
BR (1) BR112017014179A2 (ar)
CA (2) CA3080031C (ar)
CL (1) CL2017001695A1 (ar)
CO (1) CO2017006204A2 (ar)
DK (1) DK3242877T3 (ar)
ES (1) ES2861050T3 (ar)
HR (1) HRP20210385T1 (ar)
HU (1) HUE053567T2 (ar)
IL (2) IL252906B (ar)
JO (2) JOP20200093A1 (ar)
MX (2) MX2017009008A (ar)
PL (1) PL3242877T3 (ar)
PT (1) PT3242877T (ar)
RS (1) RS61570B1 (ar)
RU (2) RU2020141085A (ar)
SI (1) SI3242877T1 (ar)
TW (2) TWI729810B (ar)
WO (1) WO2016111381A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445350B (sv) * 1978-04-14 1986-06-16 Roussel Uclaf Oximderivat av 3-azidometyl-7-amino-tiazolyl-acetamido-cefalosporansyra och dess anvendning som antibiotika
CN1902196B (zh) 2003-12-26 2010-12-29 协和发酵麒麟株式会社 噻唑衍生物
KR20070050932A (ko) * 2004-07-27 2007-05-16 가부시키가이샤 아루떼꾸 우에노 Ｖａｐ―１ 억제 활성을 가지는 티아졸 유도체
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
PL1921077T3 (pl) 2005-08-02 2018-01-31 Kyowa Hakko Kirin Co Ltd Środek do zapobiegania i/lub leczenia zaburzenia snu
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
US20090281142A1 (en) * 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
CN101228143A (zh) * 2005-08-31 2008-07-23 安斯泰来制药株式会社 噻唑衍生物
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
CN102105168A (zh) 2008-07-23 2011-06-22 协和发酵麒麟株式会社 偏头痛治疗剂
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6266270B2 (ja) 2013-05-20 2018-01-24 セイコーインスツル株式会社 運動フォーム解析装置および運動フォーム解析方法
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول

Also Published As

Publication number Publication date
CL2017001695A1 (es) 2018-03-23
RU2020141085A (ru) 2021-02-10
US10214523B2 (en) 2019-02-26
EP3822269A1 (en) 2021-05-19
IL252906A0 (en) 2017-08-31
ES2861050T3 (es) 2021-10-05
CO2017006204A2 (es) 2017-11-10
TWI729810B (zh) 2021-06-01
JP2020193209A (ja) 2020-12-03
DK3242877T3 (da) 2021-03-08
RU2017128217A3 (ar) 2019-02-11
AU2016205657B2 (en) 2019-01-17
EP3242877A4 (en) 2018-10-17
JO3546B1 (ar) 2020-07-05
JP2018501282A (ja) 2018-01-18
RU2017128217A (ru) 2019-02-11
CN107108602A (zh) 2017-08-29
MX2021000711A (es) 2021-03-25
BR112017014179A2 (pt) 2018-03-06
HUE053567T2 (hu) 2021-07-28
US10618894B2 (en) 2020-04-14
IL252906B (en) 2020-03-31
CA2972746A1 (en) 2016-07-14
AR103380A1 (es) 2017-05-03
TW202035397A (zh) 2020-10-01
TW201639835A (zh) 2016-11-16
PL3242877T3 (pl) 2021-05-31
US20190144438A1 (en) 2019-05-16
AU2016205657A1 (en) 2017-07-13
US10894790B2 (en) 2021-01-19
US20180002326A1 (en) 2018-01-04
HRP20210385T1 (hr) 2021-04-16
EP3242877A1 (en) 2017-11-15
EP3242877B1 (en) 2020-12-16
SI3242877T1 (sl) 2021-04-30
JP7068402B2 (ja) 2022-05-16
US20200216438A1 (en) 2020-07-09
RU2738937C2 (ru) 2020-12-18
PT3242877T (pt) 2021-03-11
JP6770962B2 (ja) 2020-10-21
MX2017009008A (es) 2017-09-27
WO2016111381A1 (en) 2016-07-14
CN107108602B (zh) 2021-08-03
RS61570B1 (sr) 2021-04-29
TWI732748B (zh) 2021-07-11
CA2972746C (en) 2020-07-07
CA3080031A1 (en) 2016-07-14
IL272811A (en) 2020-04-30
CA3080031C (en) 2022-04-12

Similar Documents

Publication Publication Date Title
IL256624A (en) Pharmaceuticals and their pharmaceutical preparations for the treatment of inflammatory disorders
EA201990833A1 (ru) Соединение пиридина
BR112015019627A2 (pt) amidas heterocíclicas como inibidores de quinases
PH12015502047A1 (en) Novel pyrimidine and pyridine compounds and their usage
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
MD3882250T2 (ro) Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK
TW201613904A (en) Pyridone derivatives containing tetrahydropyranylmethyl group
MX2015017254A (es) Un metodo para producir 2,3-dicloro-5-(triclorometil)piridina.
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2018005133A (es) Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos.
MX362102B (es) Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo.
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
EA201891769A1 (ru) СПОСОБ ПОЛУЧЕНИЯ СОЕДИНЕНИЯ ПИРРОЛО[3,2-d]ПИРИМИДИНА И ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
MX2015011660A (es) Derivados der 6-[4-(1h-imidazol-2-il)piperidin-1-il]pirimidin-4-am ina como moduladores de la actividad de cinasa.
MX2021000711A (es) Metodo de produccion de derivado de tiazol.
MX2016008898A (es) Antagonistas selectivos de nr2b.
IL264780B (en) A method for producing 2-(3,6-dihalopyridin-2-yl)-3h-imidazolo[4,5-c]pyridine derivatives and similar compounds by reacting a 3h-imidazolo[4,5-c]pyridine derivative with a base Organometallic zinc-amine
NZ707946A (en) Hydantoin derivative
EA201791881A1 (ru) Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt
MX367267B (es) Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h -imidazo[4,5-b]piridin-2-il)piridin-2-amina.
PH12015502486A1 (en) N-(2-fluoro-2-phenethyl)carboxamides as nematicides and endoparasiticides
GEP20186922B (en) Aminoester derivatives
TW201613856A (en) Method for producing harmful-organism control agent, and intermediate thereof